Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
EPA's Endocrine Disruptor Screening Program (EDSP) was implemented in 2009-2010 with the issuance of test orders requiring manufacturers and registrants of 58 pesticide active ingredients and nine pesticide inert/high production volume chemicals to evaluate the potential of these chemicals to interact with the estrogen, androgen and thyroid hormone systems. The required endocrine screening will be conducted over the next 2-3years. Based on estimates of the impacted sectors, costs are at least $750,000-$1,000,000 per substance if all of the Tier 1 assays must be conducted. The screening will entail evaluation of responses in EPA's Tier 1 Endocrine Screening Battery (EDSP ESB), consisting of 11 distinct in vitro and in vivo assays. We reviewed the details of each test method and describe the critical factors integral to the design and conduct of the EDSP ESB assays as well as the limitations related to specificity and sensitivity. We discuss challenges to evaluating each assay, identify significant shortcomings, and make recommendations to enhance interpretation of results. Factors that affect the length of time necessary to complete the EDSP ESB for any particular substance are presented, and based on the overall analysis, we recommend a sequence for running the EDSP ESB assays. It is imperative that a structured, systematic weight of evidence framework is promptly developed, subjected to peer review and adopted. This will help to ensure an objective analysis of the results of the required EDSP screening, consistent integration of results across the EDSP ESB assays, and consistent decision making as to whether subsequent testing for adverse effects is needed. Based upon the limitations of the current EPA EDSP ESB, we concur with the Agency's Scientific Advisory Panel's recommendation that after the initial set of substances has been screened, the EDSP ESB should pause so that the results can be fully analyzed to determine the value of the existing assays. After this analysis, assays that are unnecessarily redundant or that lack endocrine specificity should be eliminated and if necessary, replaced by new or revised screens that are more mechanistically specific, rapid, reliable, and cost effective.
Applied Pharmacology and Toxicology, Inc., 2250 NW 24th Avenue, Gainesville, FL 32605, USA. cjborgert@apt-pharmatox.com
Christopher J
CJ
Borgert
Ellen M
EM
Mihaich
Terry F
TF
Quill
M S
MS
Marty
Steven L
SL
Levine
Richard A
RA
Becker
D000818:Animals; D003627:Data Interpretation, Statistical; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data; D052244:Endocrine Disruptors / Q000633:toxicity*; D006801:Humans; D017410:Practice Guidelines as Topic / Q000592:standards*; D018675:Toxicity Tests / Q000379:methods / Q000592:standards; D014481:United States; D014484:United States Environmental Protection Agency / Q000592:standards* / Q000706:statistics & numerical data
D052244:Endocrine Disruptors